These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37013108)

  • 1. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy.
    Liang I; Chu G; Zielinski R
    Case Rep Oncol; 2023; 16(1):182-187. PubMed ID: 37013108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
    Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
    Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab.
    Yamano T; Hamakawa M; Akaike Y; Ishida T
    Clin Case Rep; 2024 Jul; 12(7):e9153. PubMed ID: 38962456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab-induced immune-related sclerosing cholangitis.
    Li Y; Stewart L; Tang S; McWhirter E
    BMJ Case Rep; 2023 Nov; 16(11):. PubMed ID: 37914171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
    Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y
    World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
    Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K
    Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.
    Ooi R; Tobino K; Sakabe M; Kawabata T; Hiramatsu Y; Sueyasu T; Yoshimine K
    Respir Med Case Rep; 2020; 31():101197. PubMed ID: 32944497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
    Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
    Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient with primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis variant syndrome.
    Terziroli Beretta-Piccoli B; Mazzucchelli L; Taiana C; Mossi G; Usai C; Vergani D; Mieli-Vergani G
    J Transl Autoimmun; 2020; 3():100033. PubMed ID: 32743518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient.
    Matsumoto S; Watanabe K; Kobayashi N; Irie K; Yamanaka S; Kaneko T
    Respirol Case Rep; 2020 Jul; 8(5):e00560. PubMed ID: 32284868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical presentation of autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome associated with hypereosinophilia: a case report and review of the literature.
    Hatami B; Rahmani Seraji H; Fallahi M
    J Med Case Rep; 2021 Oct; 15(1):524. PubMed ID: 34663468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.
    Zen Y; Chen YY; Jeng YM; Tsai HW; Yeh MM
    Histopathology; 2020 Feb; 76(3):470-480. PubMed ID: 31550390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of pembrolizumab-induced sclerosing cholangitis that was responsive to high-dose steroid therapy].
    Nagasawa S; Miyazaki M; Morita Y; Tanaka K; Yada M; Masumoto A; Motomura K
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(10):981-990. PubMed ID: 34629349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sclerosing cholangitis as a complication of Langerhans'cell histiocytosis].
    Pagnoux C; Hayem G; Roux F; Palazzo E; Meyer O
    Rev Med Interne; 2003 May; 24(5):324-7. PubMed ID: 12763179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature.
    Hori H; Fujita K; Nishio A; Nishijima M; Inaba M; Anami T; Matsui S; Kitamura Y; Matsuoka R; Watanabe A
    Clin J Gastroenterol; 2022 Apr; 15(2):475-479. PubMed ID: 35072901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.